Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro

Yakugaku Zasshi

Volumn 128, Issue 10, 2008, Pages 1459-1465

  Fukazawa, Tominaga ^a   Yajima, Kanako ^b   Miyamoto, Yohei ^a  

^a TORAY INDUSTRIES INC   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Beraprost; Chronic occlusive disease; Cytochrome P450; Drug drug interaction; Primary pulmonary hypertension; Prostacyclin

Indexed keywords

BERAPROST; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANTIHYPERTENSIVE AGENTS; ARTERIAL OCCLUSIVE DISEASES; CHRONIC DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; ISOENZYMES; MICROSOMES, LIVER; PLATELET AGGREGATION INHIBITORS;

EID: 53249121836     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.128.1459     Document Type: Article

References (39)

1. Ohno K., Nagase K., Matsumoto K., Nishiyama H., Nishio S., Adv. Prostaglandin Thromboxane Leukotriene Res., 15, 279-281 (1985).
2. Nishio S., Matsuura H., Kanai N., Fukatsu Y., Hirano T., Nishikawa N., Kameoka K., Umetsu T., Jpn. J. Pharmacol., 47, 1-10 (1988).
3. Kajikawa N., Nogimori K., Murata T., Nishio S., Uchiyama S., Arznein.-Forsch./Drug Res., 39, 495-499 (1989).
4. Nishio S., Kurumatani H., Folia Pharmacol. Jpn., 117, 123-130 (2001).
5. Seyfarth H. J., Pankau H., Hammerscmidt S., Schauer J., Wirtz H., Winkler J., Chest, 128, 709-713 (2005).
6. Fujitani K., Kambayashi J., Murata K., Yano Y., Shinozaki K., Yukawa M., Sakon M., Murata T., Kawasaki T., Shiba E., Mori T., Pharmacol. Res., 31, 121-125 (1995).
7. Warot D., Berlin I., Aymard G., Ankri A., Fabry C., Besse B., Lechat P., Diquet B., Fundam. Clin. Pharmacol., 14, 231-6 (2000).
8. Lin J., Lu AYH., Clin. Pharmacokinet., 35, 361-390 (1998).
9. Brooks P. M., Buchanan W. W., Grove M., Downie W. W., Ann. Rheum. Dis., 35, 339-343 (1976).
10. Ogiso T., Iwaki M., Konishi Y., J. Pharm. Dyn., 5, 829-840 (1982).
11. Kato R., Uji Y., Matsumoto K., Jpn. J. Clin. Pharmacol. Ther., 20, 515-527 (1989).
12. Hooper W. D., Franklin M. E., Glue P., Banfield C. R., Radwanski E., McLaughlin D. B., McIntyre M. E., Dickinson R. G., Eadie M. J., Epilepsia, 37, 91-97 (1996).
13. Addison R. S., Parker-Scott S. L., Eadie M. J., Hooper W. D., Dickinson R. G., Eur. J. Clin. Pharmacol., 56, 715-721 (2000).
14. Gonzalez F. J., Pharmacol. Ther., 45, 1-38 (1990).
15. Guengerich F. P., FASEB J., 6, 745-748 (1992).
16. Dekant W., Frischamann C., Speerschneider P., Xenobiotica, 25, 1259-1265, (1995).
17. Dislerath L. M., Reilly P. E., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P., J. Biol. Chem., 260, 9057-9067, (1985).
18. Greenlee W., Poland A., J. Pharm. Exp. Ther., 205, 596-605, (1978).
19. Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolf T., Waxman D. J., J. Biol. Chem., 261, 5051-5060, (1986).
20. Krobach T., Mathys D., Gut J., Catin T., Mayer U. A., Anal. Biochem., 162, 24-32, (1987).
21. Miners J. O., Smith K. J., Robson R. A., Mac Manus M. E., Veronese M. E., Birkett D. J., Biochem. Pharmacol., 37, 1137-1144, (1988).
22. Shimada T., Misono S. K., Guengerich F. P., J. Biol. Chem., 261, 909-921, (1986).
23. Borenfreund E., Puerner J. A., J. Tissue Culture Methods, 9, 7-9 (1984).
24. Chesne C., Guillouzo A., Cryobiology, 25, 323-330 (1988).
25. Chesne C. Guyomard C., Fautrel A., Poullain M. G., Fremond B., De Jong H., Guillouzo A., Hepatology, 18, 406-414 (1993).
26. Guguen-Guillouzo C., Guillouzo A., "Isolated and cultured hepatocytes", eds. by Guillouzo A., Guguen-Guillouzo C., Inserm Paris & John Libbey Eurotext, London, 1986, pp. 1-12.
27. Guillouzo A., Chesne C., "Epithelial cell culture: A practical approach" ed. by Shaw J. A., IRL Press, Oxford, 1996, pp. 67-85.
28. Moldeus P., Biochem. Pharmacol., 27, 2859-2863 (1978).
29. Testino S. A. Jr, Patonay G., J. Pharm. Biomed. Anal., 30, 1459-1467, (2003).
30. Walsky R. L., Obach R. S., Drug Metab. Dispos., 32, 647-660, (2004).
31. Cai X., Wang R. W., Edom R. W., Evans D. C., Shou M., Rodrigues A. D., Liu W., Dean D. C., Baillie T. A., Drug Metab. Dispos., 32, 584-586, (2004).
32. Wen X., Wang J. S., Backman J. T., Laitila J., Neuvonen P. J., Drug Metab. Dispos., 30, 631-635, (2002).
33. Bradford M., Anal. Biochem., 72, 248-254 (1976).
34. Moody G. C., Griffin S. J., Mather A. N., McGinnity D. F., Riley R. J., Xenobiotica, 29, 53-75, (1999).
35. Yamazaki H., Shimada T., Xenobiotica, 29, 231-241, (1999).
36. Bálint G. A., Pap A., Karácsony G., Varró V., Szabó I., Acta Med. Hung., 41, 247-252 (1984).
37. Tsai C. F., Lii C. K., Yang J. J., Liu K., Lin W. L., Chen H. W., Nutr. Cancer, 41, 188-195 (2001).
38. Li C. C., Shen H. L., Lii C. K., Liu K. L., Yang J. J., Chen H. W., Biochem. Biophys. Res. Commun., 327, 424-430 (2005).
39. Kato R., Uji Y., Matsumoto K., Jpn. J. Clin. Ther., 20, 515-527 (1989).